{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:51Z","timestamp":1788844251701,"version":"build-2803163510"},"reference-count":131,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["CA291437"],"award-info":[{"award-number":["CA291437"]}]},{"name":"NIH","award":["CA294800"],"award-info":[{"award-number":["CA294800"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Epstein\u2013Barr virus (EBV) is an oncogenic human gammaherpesvirus that is prevalent worldwide. Although over 95% of the world\u2019s population harbors this pathogen, the vast majority of infections are asymptomatic, largely due to immune system involvement. However, in certain situations, such as when individuals are immunocompromised, the immune system can lose control of EBV suppression, leading to oncogenesis. While standard chemotherapeutic regimens can be effective against some EBV-associated cancers, these treatments can be toxic to some patients, and disease relapse and\/or drug resistance can develop. Additionally, no human vaccine currently exists for EBV. In recent years, biotherapy has become a promising avenue for the clinical management of EBV-positive cancers. As early detection is often correlated with a more positive prognosis, identification of reliable EBV biomarkers has also come into focus. In this review, we summarize advancements made over the last five years in immunotherapy use for EBV-positive cancers and in EBV biomarker identification to detect both EBV infection and biotherapy response.<\/jats:p>","DOI":"10.3390\/v18090980","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:30:02Z","timestamp":1788798602000},"page":"980","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Biomarkers and Biotherapies for EBV-Associated Cancers"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-1798","authenticated-orcid":false,"given":"Maria C.","family":"White","sequence":"first","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-1774","authenticated-orcid":false,"given":"Blossom","family":"Damania","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1038\/s41467-025-60836-9","article-title":"Genomic landscape of virus-associated cancers","volume":"16","author":"Nam","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: Biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/scbi.1996.0027","article-title":"EBV infection of T cells: Potential role in malignant transformation","volume":"7","author":"Kelleher","year":"1996","journal-title":"Semin. Cancer Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1158\/0008-5472.CAN-03-1562","article-title":"Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells","volume":"64","author":"Isobe","year":"2004","journal-title":"Cancer Res."},{"key":"ref_5","first-page":"56","article-title":"Epstein-Barr Virus-Positive Leiomyosarcoma in Immunocompetent Patients","volume":"40","author":"Alp","year":"2024","journal-title":"Turk Patoloji Derg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2016653118","DOI":"10.1073\/pnas.2016653118","article-title":"Kaposi\u2019s sarcoma herpesvirus is associated with osteosarcoma in Xinjiang populations","volume":"118","author":"Chen","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16046","DOI":"10.1073\/pnas.1901314116","article-title":"Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection","volume":"116","author":"Buschle","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18093","DOI":"10.1073\/pnas.0509311102","article-title":"Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells","volume":"102","author":"Souza","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","first-page":"100505","article-title":"A thorough insight into the life cycle of the Epstein-Barr virus. From the molecular to the organismal level","volume":"9","author":"Zaremba","year":"2025","journal-title":"Curr. Res. Microb. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Price, A.M., and Luftig, M.A. (2015). To be or not IIb: A multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004656"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.micinf.2004.04.014","article-title":"The immune response to Epstein-Barr virus","volume":"6","author":"Callan","year":"2004","journal-title":"Microbes Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"167214","DOI":"10.1016\/j.jmb.2021.167214","article-title":"Activation and Evasion of Innate Immunity by Gammaherpesviruses","volume":"434","author":"Lange","year":"2022","journal-title":"J. Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Zhang, Q., Zhang, B., Dai, Y., Gao, Y., Li, C., Yu, Y., and Li, C. (2024). Epstein-Barr Viruses: Their Immune Evasion Strategies and Implications for Autoimmune Diseases. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158160"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Albanese, M., Tagawa, T., and Hammerschmidt, W. (2022). Strategies of Epstein-Barr virus to evade innate antiviral immunity of its human host. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.955603"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101438","DOI":"10.1016\/j.coviro.2024.101438","article-title":"Epstein-Barr virus lytic replication and cancer","volume":"70","author":"Li","year":"2025","journal-title":"Curr. Opin. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"SoRelle, E.D., Haynes, L.E., Willard, K.A., Chang, B., Ch\u2019ng, J., Christofk, H., and Luftig, M.A. (2024). Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression. PLoS Pathog., 20.","DOI":"10.1101\/2024.06.14.598975"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rmv.1786","article-title":"Modes of infection and oncogenesis by the Epstein-Barr virus","volume":"24","author":"Murata","year":"2014","journal-title":"Rev. Med. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70501","DOI":"10.1002\/jmv.70501","article-title":"EBV Latency Programs: Molecular and Epigenetic Regulation and Its Role in Disease Pathogenesis","volume":"97","author":"Lyu","year":"2025","journal-title":"J. Med. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Li, W., Duan, X., Chen, X., Zhan, M., Peng, H., Meng, Y., Li, X., Li, X.Y., Pang, G., and Dou, X. (2022). Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1079515"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cgh.2022.07.042","article-title":"Estimating the Global Burden of Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review and Meta-Analysis","volume":"21","author":"Hirabayashi","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513, 202\u2013209.","DOI":"10.1038\/nature13480"},{"key":"ref_22","first-page":"1397","article-title":"Epstein-Barr virus and Burkitt lymphoma","volume":"60","author":"Brady","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Song, C.G., Huang, J.J., Li, Y.J., Xia, Y., Wang, Y., Bi, X.W., Jiang, W.Q., Huang, H.Q., Lin, T.Y., and Li, Z.M. (2015). Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133973"},{"key":"ref_24","first-page":"e2009013","article-title":"EBV in Hodgkin Lymphoma","volume":"1","author":"Massini","year":"2009","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kimura, H., and Fujiwara, S. (2018). Overview of EBV-Associated T\/NK-Cell Lymphoproliferative Diseases. Front. Pediatr., 6.","DOI":"10.3389\/fped.2018.00417"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2147\/OTT.S188148","article-title":"Management of recurrent nasopharyngeal carcinoma: Current perspectives","volume":"12","author":"Perri","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sun, K., Jia, K., Lv, H., Wang, S.Q., Wu, Y., Lei, H., and Chen, X. (2020). EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.583463"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_29","first-page":"17515","article-title":"Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: A meta-analysis","volume":"8","author":"Meng","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/CCO.0000000000000889","article-title":"EBV-associated NK and T-cell lymphoid neoplasms","volume":"34","author":"Kimura","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients\u2014BCSH and BTS Guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-Transplantation Lymphoproliferative Disorders in Adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa2301496","article-title":"Anti-Epstein-Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer","volume":"389","author":"Li","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1158\/1078-0432.CCR-22-1600","article-title":"Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma","volume":"28","author":"Paudel","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s13046-018-0953-6","article-title":"EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-\u03baB and Erk1\/2 pathways","volume":"37","author":"Lin","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1038\/s41598-024-58233-1","article-title":"Plasma Epstein-Barr virus microRNA BART8-3p as a potential biomarker for detection and prognostic prediction in early nasopharyngeal carcinoma","volume":"14","author":"Lin","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/ijc.34561","article-title":"Saliva biopsy: Detecting the difference of EBV DNA methylation in the diagnosis of nasopharyngeal carcinoma","volume":"153","author":"Zheng","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1002\/mco2.673","article-title":"Detection of Epstein\u2014Barr virus DNA methylation as tumor markers of nasopharyngeal carcinoma patients in saliva, oropharyngeal swab, oral swab, and mouthwash","volume":"5","author":"Zheng","year":"2024","journal-title":"MedComm"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","article-title":"Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma","volume":"51","author":"Xu","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e0292725","DOI":"10.1128\/spectrum.02927-25","article-title":"Targeted Epstein-Barr virus capture sequencing identifies BBLF4-L322M as an independent prognostic variant in nasopharyngeal carcinoma","volume":"14","author":"Luo","year":"2026","journal-title":"Microbiol. Spectr."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Qian, X., Chen, H., and Tao, Y. (2023). Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1146898"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","article-title":"Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102096","DOI":"10.1016\/j.xcrm.2025.102096","article-title":"Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1600-065X.2008.00650.x","article-title":"Regulation of T-cell responses by PTEN","volume":"224","author":"Buckler","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12951-025-03315-z","article-title":"PTEN as a prognostic factor for radiotherapy plus immunotherapy response in nasopharyngeal carcinoma","volume":"23","author":"Guo","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ijc.32490","article-title":"Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients","volume":"146","author":"Qiu","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Alberti, A., Stocker, G., Lordick, F., Hacker, U.T., Kobitzsch, B., Haffner, I., Baiocchi, G.L., Zamparini, M., Tiberio, G.A.M., and Baronchelli, C. (2023). Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: A multicenter, prospective study (EBV PRESAGE study). Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1276138"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Corallo, S., Lasagna, A., Filippi, B., Alaimo, D., Tortorella, A., Serra, F., Vanoli, A., and Pedrazzoli, P. (2024). Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review. Pathogens, 13.","DOI":"10.3390\/pathogens13090728"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Pyo, J.S., Kim, N.Y., and Kang, D.W. (2023). Prognostic Implication of EBV Infection in Gastric Carcinomas: A Systematic Review and Meta-Analysis. Medicina, 59.","DOI":"10.3390\/medicina59050834"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e004080","DOI":"10.1136\/jitc-2021-004080","article-title":"Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer","volume":"10","author":"Bai","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1938381","DOI":"10.1080\/2162402X.2021.1938381","article-title":"The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer","volume":"10","author":"Wei","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s13402-020-00538-0","article-title":"EBV-miR-BART10-3p and EBV-miR-BART22 promote metastasis of EBV-associated gastric carcinoma by activating the canonical Wnt signaling pathway","volume":"43","author":"Dong","year":"2020","journal-title":"Cell. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Abusalah, M.A.H., Irekeola, A.A., Hanim Shueb, R., Jarrar, M., and Yean Yean, C. (2022). Prognostic Epstein-Barr Virus (EBV) miRNA biomarkers for survival outcome in EBV-associated epithelial malignancies: Systematic review and meta-analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0266893"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12967-024-04859-8","article-title":"A novel biomarker associated with EBV infection improves response prediction of immunotherapy in gastric cancer","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"20503121211054991","DOI":"10.1177\/20503121211054991","article-title":"Evaluation of plasma Epstein-Barr virus DNA as a biomarker for Epstein-Barr virus-associated Hodgkin lymphoma","volume":"9","author":"Usha","year":"2021","journal-title":"SAGE Open Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ijc.33802","article-title":"Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group","volume":"150","author":"Shen","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5045\/br.2021.2021028","article-title":"Clinical impact of cell-free serum Epstein-Barr virus status in patients with newly diagnosed malignant lymphoma","volume":"56","author":"Baek","year":"2021","journal-title":"Blood Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/QAD.0000000000002839","article-title":"Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas","volume":"35","author":"Lupo","year":"2021","journal-title":"Aids"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13027-026-00758-3","article-title":"Plasma EBV DNA dynamics during chemotherapy as a prognostic biomarker in AIDS-related non-Hodgkin lymphoma","volume":"21","author":"Wang","year":"2026","journal-title":"Infect. Agent. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/10428194.2022.2045595","article-title":"Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma","volume":"63","author":"Zhou","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00277-023-05260-z","article-title":"Dynamic changes in circulating EBV-DNA load during treatment have prognostic values in EBV(+) DLBCL-NOS: A Chinese cohort study","volume":"102","author":"Xing","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00277-026-06912-6","article-title":"Low hemoglobin as a novel prognostic biomarker in EBV-positive diffuse large B-cell lymphoma patients: A clinical feature analysis of 99 cases from Zhejiang, Southeast China","volume":"105","author":"Huang","year":"2026","journal-title":"Ann. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"105320","DOI":"10.1016\/j.jcv.2022.105320","article-title":"Plasma EBV-DNA and peripheral blood mononuclear cell EBV-DNA have disparate clinical relevance in patients with extranodal NK\/T-cell lymphoma","volume":"157","author":"Yan","year":"2022","journal-title":"J. Clin. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hon.2998","article-title":"The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases","volume":"40","author":"Zheng","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13027-026-00752-9","article-title":"Prognostic significance of quantitative EBV biomarkers in extranodal NK\/T-cell lymphoma: A meta-analysis of EBV DNA load and EBER-positive cell proportion","volume":"21","author":"Wang","year":"2026","journal-title":"Infect. Agent. Cancer"},{"key":"ref_66","first-page":"2714","article-title":"Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer\/T-cell lymphoma with pegaspargase-based treatment: Long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study","volume":"110","author":"Zhong","year":"2025","journal-title":"Haematologica"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"13993","DOI":"10.1128\/JVI.79.22.13993-14003.2005","article-title":"Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model","volume":"79","author":"Hong","year":"2005","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/CMR.00006-09","article-title":"Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder","volume":"23","author":"Gulley","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-017-09798-7","article-title":"Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD","volume":"7","author":"Habib","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Lupo, J., Wielandts, A.S., Buisson, M., Consortium, C., Habib, M., Hamoudi, M., Morand, P., Verduyn-Lunel, F., Caillard, S., and Drouet, E. (2022). High Predictive Value of the Soluble ZEBRA Antigen (Epstein-Barr Virus Trans-Activator Zta) in Transplant Patients with PTLD. Pathogens, 11.","DOI":"10.3390\/pathogens11080928"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/infdis\/jiaf477","article-title":"The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients","volume":"233","author":"Wareham","year":"2026","journal-title":"J. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Sen, A., Enriquez, J., Rao, M., Glass, M., Balachandran, Y., Syed, S., Twist, C.J., Weinberg, K., Boyd, S.D., and Bernstein, D. (2022). Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.994552"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"115676","DOI":"10.1016\/j.bcp.2023.115676","article-title":"EBV-encoded miRNAs BHRF1-1 and BART2-5p aggravate post- transplant lymphoproliferative disorder via LZTS2-PI3K-AKT axis","volume":"214","author":"Ji","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13148-022-01255-1","article-title":"Methyl-qPCR: A new method to investigate Epstein-Barr virus infection in post-transplant lymphoproliferative diseases","volume":"14","author":"Borde","year":"2022","journal-title":"Clin. Epigenet."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-17-2656","article-title":"Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials","volume":"24","author":"Chen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102058","DOI":"10.1016\/j.tranon.2024.102058","article-title":"Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A retrospective study","volume":"48","author":"He","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2026.0020","article-title":"First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial","volume":"12","author":"Yang","year":"2026","journal-title":"JAMA Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): An open-label, randomized, phase III trial","volume":"34","author":"Chan","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Bei, W., Wang, L., Lu, N., Xu, C., Liang, H., Ke, L., Ye, Y., He, S., and Dong, S. (2025). Efficacy and safety of cadonilimab (PD-1\/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: A single-arm, open-label, phase 2 trial. BMC Med., 23.","DOI":"10.1186\/s12916-025-03985-4"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"200986","DOI":"10.1016\/j.omton.2025.200986","article-title":"Epstein-Barr virus mRNA vaccine synergizes with NK cells to enhance nasopharyngeal carcinoma eradication in humanized mice","volume":"33","author":"Huang","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17588359251396619","DOI":"10.1177\/17588359251396619","article-title":"Therapeutic opportunities in EBV-positive gastric cancer subtypes","volume":"17","author":"Owen","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e010201","DOI":"10.1136\/jitc-2024-010201","article-title":"Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: Implications for immunotherapy","volume":"12","author":"McMiller","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Yaringa\u00f1o, J., Bl\u00e1zquez-L\u00f3pez, A., Acosta, D., Landolfi, S., Castro-Boix, S., Aguilar, S., Vivancos, A., \u00c9lez, E., and Ter\u00e1n-Brage, E. (2026). Immune checkpoint inhibition in Epstein-Barr virus associated gastric cancer: A case report highlighting the role of biomarker-driven treatment selection. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1772402"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10120-025-01618-6","article-title":"Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy","volume":"28","author":"Kim","year":"2025","journal-title":"Gastric Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10120-023-01435-9","article-title":"Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: A multicenter phase Ib\/II study","volume":"27","author":"Lee","year":"2024","journal-title":"Gastric Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41419-025-08251-2","article-title":"An EBNA1-YAP signaling axis drives immune escape through CD276 in EBV-associated gastric cancer","volume":"17","author":"Huang","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00262-020-02787-2","article-title":"Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma","volume":"70","author":"Jimenez","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin\u2019s Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"eade8520","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"ref_95","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/bloodadvances.2022008116","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen","year":"2023","journal-title":"Blood Adv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: Pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-21-2023","article-title":"Tislelizumab for Relapsed\/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis","volume":"28","author":"Song","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood-2025-3624","article-title":"Smart start with tislelizumab as frontline treatment in advanced-stage classical Hodgkin lymphoma: A PET-adapted, chemotherapy-sparing phase 2 study","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Jimenez, O., Mangiaterra, T., Colli, S., Garc\u00eda Lombardi, M., Preciado, M.V., De Matteo, E., and Chabay, P. (2022). PD-1 and LAG-3 expression in EBV-associated pediatric Hodgkin lymphoma has influence on survival. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.957208"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1038\/s41467-025-64862-5","article-title":"A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors","volume":"16","author":"Quasem","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: Final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase\u20091 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","article-title":"CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease","volume":"18","author":"Slabik","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"114797","DOI":"10.1016\/j.biopha.2023.114797","article-title":"Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350\/CD89-targeted bispecific antibody","volume":"163","author":"He","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Braun, T., Pruene, A., Darguzyte, M., Vom Stein, A.F., Nguyen, P.H., Wagner, D.L., Kath, J., Roig-Merino, A., Heuser, M., and Riehm, L.L. (2023). Non-viral TRAC-knocked-in CD19(KI)CAR-T and gp350(KI)CAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1086433"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12967-025-06188-w","article-title":"Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: Pre-clinical development of gp350 CAR-T","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Liu, R., Yang, F., Ma, L., Guo, Y., Cao, M., Fu, Z., Deng, B., Zheng, Q., Chen, C., and Li, D. (2025). CAR T- cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patients. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1566938"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/blood.2024026831","article-title":"Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma","volume":"145","author":"Samples","year":"2025","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/bloodadvances.2021005788","article-title":"Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: A noncomparative cohort analysis","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood.2024027347","article-title":"Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: The ZUMA-12 study","volume":"145","author":"Chavez","year":"2025","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e769","DOI":"10.1097\/CAD.0000000000001187","article-title":"Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: A case report","volume":"33","author":"Yu","year":"2022","journal-title":"Anticancer Drugs"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s44313-024-00042-6","article-title":"PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: A retrospective analysis","volume":"59","author":"Li","year":"2024","journal-title":"Blood Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Li, H., Song, W., Wu, J., Shi, Z., Gao, Y., Li, J., Han, L., Zhang, J., Li, Z., and Li, Y. (2023). CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK\/T cell lymphoma. BMC Med., 21.","DOI":"10.1186\/s12916-023-03040-0"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00277-021-04558-0","article-title":"Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK\/T lymphoma: Results of a multicenter study","volume":"100","author":"Kim","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3324\/haematol.2021.278301","article-title":"A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas","volume":"106","author":"Kim","year":"2021","journal-title":"Haematologica"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4143\/crt.2023.1042","article-title":"Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK\/T-Cell Lymphoma in Korea","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13023-023-02861-9","article-title":"Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children","volume":"18","author":"Chen","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"796.e7","DOI":"10.1016\/j.cmi.2023.01.017","article-title":"PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection","volume":"29","author":"Song","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S2352-3026(24)00066-8","article-title":"First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer\/T cell lymphoma (SPIRIT): A multicentre, single-arm, phase 2 trial","volume":"11","author":"Tian","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/bloodadvances.2023011626","article-title":"Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol","volume":"8","author":"Nikiforow","year":"2024","journal-title":"Blood Adv."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","article-title":"Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): A phase 3, multicentre, open-label trial","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"S506","DOI":"10.1016\/j.jtct.2025.01.806","article-title":"Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein\u2013Barr Virus\u2013Driven Posttransplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy","volume":"31","author":"Ghobadi","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/bloodadvances.2023010832","article-title":"Durable immunity to EBV after rituximab and third-party LMP-specific T cells: A Children\u2019s Oncology Group study","volume":"8","author":"Wistinghausen","year":"2024","journal-title":"Blood Adv."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e180216","DOI":"10.1172\/JCI180216","article-title":"A large-scale population-based study reveals that gp42-IgG antibody is protective against EBV-associated nasopharyngeal carcinoma","volume":"135","author":"Kong","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41541-026-01486-w","article-title":"Recent advances in Epstein-Barr virus vaccines development from mechanistic exploration to clinical translation","volume":"11","author":"Hong","year":"2026","journal-title":"npj Vaccines"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"102618","DOI":"10.1016\/j.xcrm.2026.102618","article-title":"Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development","volume":"7","author":"Chhan","year":"2026","journal-title":"Cell Rep. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/9\/980\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:28:54Z","timestamp":1788841734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/9\/980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":131,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["v18090980"],"URL":"https:\/\/doi.org\/10.3390\/v18090980","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]}}}